Omeros Corporation Revenue and Competitors

Seattle, WA USA

Location

$965.4M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Omeros Corporation's estimated annual revenue is currently $47.9M per year.(i)
  • Omeros Corporation received $210.0M in venture funding in November 2018.
  • Omeros Corporation's estimated revenue per employee is $203,809
  • Omeros Corporation's total funding is $965.4M.

Employee Data

  • Omeros Corporation has 235 Employees.(i)
  • Omeros Corporation grew their employee count by 0% last year.

Omeros Corporation's People

NameTitleEmail/Phone
1
Associate VP, FP&AReveal Email/Phone
2
Associate VP Clinical OperationsReveal Email/Phone
3
Chief Medical OfficerReveal Email/Phone
4
Associate VP, Structural BiologyReveal Email/Phone
5
Chief Accounting OfficerReveal Email/Phone
6
Associate VP, Clinical DevelopmentReveal Email/Phone
7
Associate VP Regulatory AffairsReveal Email/Phone
8
Chief Business Development OfficerReveal Email/Phone
9
VP General Counsel and SecretaryReveal Email/Phone
10
VP CMC | CMC & Technical Operations LeaderReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.9M60%N/AN/A
#2
$0.9M60%N/AN/A
#3
$5.1M336%N/AN/A
#4
$5.7M3742%N/AN/A
#5
$1.4M18-10%N/AN/A
#6
$3.7M48-21%$16MN/A
#7
$1.1M70%N/AN/A
#8
$0.8M5-81%N/AN/A
#9
$2.5M16-27%N/AN/A
#10
$0.8M5-17%N/AN/A
Add Company

What Is Omeros Corporation?

Omeros is a Seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.

keywords:Biotechnology,E-Commerce,Healthcare,Human Resources Hr,Marketing,Pharmaceuticals

$965.4M

Total Funding

235

Number of Employees

$47.9M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Omeros Corporation News

2022-04-17 - 2022-04-20 | NDAQ:OMER | Press Release | Omeros ...

Omeros Announces Journal of Clinical Oncology Publication Detailing Pivotal ... Omeros Corporation (Nasdaq: OMER) today announced the online...

2022-04-17 - Omeros Announces Journal of Clinical Oncology Publication ...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the online publication of a manuscript detailing the results of...

2022-04-13 - Omeros Corporation (OMER) Stock: Do Analysts Think You Should Accumulate?

Analysts who follow Omeros Corporation (OMER) on average expect it to add 195.58% over the next twelve months. Those same analysts give the...

2019-09-08 - Omeros Corporation (OMER) Momentum to a Halt as Shares Drop -2.15% For The Week

Omeros Corporation (OMER) have moved lower over the course of the past week revealing negative downward near-term momentum for the ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$82.1M2353%$41.4M
#2
$37.5M23524%N/A
#3
$53.2M2369%N/A
#4
$70.1M2369%N/A
#5
$70.1M2365%N/A

Omeros Corporation Funding

DateAmountRoundLead InvestorsReference
2006-09-08$UndisclosedUndisclosedARCH Venture Partners, Aravis VentureArticle
2007-01-12$9.0MUndisclosedArticle
2007-02-13$63.0MEMultipleArticle
2008-09-25$20.0MUndisclosedBlueCrest Capital FinanceArticle
2010-07-30$40.0MUndisclosedReedland Capital PartnersArticle
2010-10-26$20.0MUndisclosedVulcan CapitalArticle
2012-06-27$34.5MUndisclosedCowen and Company LLC , Deutsche Bank Securities IncArticle
2013-05-10$16.2MUndisclosedRA Capital ManagementArticle
2014-03-06$32.0MUndisclosedArticle
2014-03-17$35.0MUndisclosedCowen and Company, LLCArticle
2014-03-20$40.2MUndisclosedCowen and Company, LLCArticle
2015-01-29$UndisclosedUndisclosedCowen and Company, LLCArticle
2015-02-05$79.1MUndisclosedCowen and Company, LLCArticle
2016-01-07$70.0MUndisclosedOxford FinanceArticle
2016-05-18$20.0MUndisclosedOxford Finance LLCArticle
2016-08-12$40.0MUndisclosedCantor Fitzgerald & CoArticle
2016-10-28$125.0MUndisclosedCRG LPArticle
2017-08-23$78.5MUndisclosedCantor Fitzgerald & CoArticle
2018-11-09$210.0MUndisclosedCantor Fitzgerald & CoArticle